Being named as the prime contractor on a significant government contract like the ARPA-H IDIQ, valued at $500 million, directly impacts ASGN's potential for revenue growth and enhances its reputation in the market. This development is likely to be viewed positively by investors, as it not only demonstrates the company's capability in securing large contracts but also positions it for future growth in the health sector.